{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:07:58Z","timestamp":1764587278255},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":3606,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1046\/j.1524-4733.2003.65241.x","type":"journal-article","created":{"date-parts":[[2003,9,18]],"date-time":"2003-09-18T10:26:28Z","timestamp":1063880788000},"page":"551-559","source":"Crossref","is-referenced-by-count":34,"title":["Validation of Health Economic Models: The Example of EVITA"],"prefix":"10.1016","volume":"6","author":[{"given":"Thomas","family":"Hammerschmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Goertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Neiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wutzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Banz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1046\/j.1524-4733.2003.65241.x_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00019053-200017050-00003","article-title":"Decision analytic modeling in the economic evaluation of health technologies: a consensus statement","volume":"17","author":"Akehurst","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib20","first-page":"33","article-title":"What is it to be a model? Trials and tribulations in economic evaluation","volume":"1","author":"McGuire","year":"2000","journal-title":"Eur J Health Econ"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: Report if the ISPOR Task Force on Good Research Practices\u2013Modeling Studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","article-title":"Modelling in economic evaluation: an unavoidable fact of life","volume":"6","author":"Buxton","year":"1997","journal-title":"Health Econ"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib50","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3","article-title":"Evaluation the cost-effectiveness of vaccination programmes: a dynamic perspective","volume":"18","author":"Edmunds","year":"1999","journal-title":"Stat Med"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1524-4733.2001.45061.x","article-title":"Modeling for health care and other policy decisions: uses, roles, and validity","volume":"4","author":"Weinstein","year":"2001","journal-title":"Value Health"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib70","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1001\/jama.283.16.2116","article-title":"Problems with the interpretation of pharmacoeconomic analyses\u2014a review of submissions to the Australian Pharmaceutical Benefit Scheme","volume":"283","author":"Hill","year":"2000","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib80","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00019053-199814030-00003","article-title":"Reporting format for economic evaluation. II. Focus on modeling studies","volume":"14","author":"Nuijten","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2753.1999.00174.x","article-title":"Systematic validation of disease models for pharmacoeconomic evaluations","volume":"5","author":"Sendi","year":"1999","journal-title":"J Eval Clin Pract"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0264-410X(02)00431-0","article-title":"The cost-effectiveness of routine childhood varicella vaccination in Germany","volume":"21","author":"Banz","year":"2003","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib110","series-title":"Assessing Medical Technologies","first-page":"144","article-title":"Technology assessment: the role of mathematical modeling","author":"Eddy","year":"1985"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/00019053-200017050-00007","article-title":"Testing the validity of cost-effectiveness models","volume":"17","author":"McCabe","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib130","series-title":"Is it You or Your Model Talking? A Framework for Validation. R-4114-AF\/A\/OSD","author":"Hodges","year":"1992"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/oxfordjournals.aje.a117238","article-title":"Theoretical epidemiological and morbidity effects of routine varicella immunization of preschool children in the United States","volume":"140","author":"Halloran","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0025-5564(94)90070-1","article-title":"Epidemiologic effects of vaccines with complex direct effects in an aged-structured population","volume":"121","author":"Halloran","year":"1994","journal-title":"Math Biosci"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(01)00276-6","article-title":"Seroprevalence of varicella-zoster virus in the German population","volume":"20","author":"Wutzler","year":"2002","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib170","unstructured":"Wagenpfeil S, Neiss A, Bisanz H, et al. Epidemiology of varicella infection to assess the burden of disease in Germany. Clin Microbiol Infect (in press)."},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00430-002-0123-4","article-title":"Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany","volume":"191","author":"Wutzler","year":"2002","journal-title":"Med Microbiol Immunol"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib190","series-title":"VIP 1998\u20132001. Prescription Index for Pharmaceuticals (Verschreibungsindex f\u00fcr Pharmazeutika)","year":"2002"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib200","series-title":"A Dictionary of Epidemiology","author":"Last","year":"1995"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib210","series-title":"Oxford Textbook of Public Health","article-title":"Mathematical models of transmission and control","author":"Anderson","year":"1991"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib220","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/bmj.319.7223.1462","article-title":"Increase in congenital rubella occurence after immunisation in Greece: retrospective survey and systematic review","volume":"319","author":"Panagiotopoulos","year":"1999","journal-title":"BMJ"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib240","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(98)00161-3","article-title":"The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France","volume":"17","author":"Coudeville","year":"1999","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib250","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0022-3476(05)83173-7","article-title":"Childhood vaccination against chickenpox: an analysis of benefits and costs","volume":"124","author":"Huse","year":"1994","journal-title":"J Pediatr"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/infdis\/174.Supplement_3.S335","article-title":"Costs and benefits of a routine varicella vaccination in German children","volume":"174","author":"Beutels","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib270","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0264-410X(98)00394-6","article-title":"A cost benefit analysis of routine varicella vaccination in Spain","volume":"17","author":"Diez-Domingo","year":"1999","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib280","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0277-9536(99)00115-X","article-title":"The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule","volume":"49","author":"Scuffham","year":"1999","journal-title":"Soc Sci Med"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib290","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0264-410X(99)00261-3","article-title":"The cost-effectiveness of varicella vaccine programs for Australia","volume":"18","author":"Scuffham","year":"2000","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib300","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost-effectiveness of varicella vaccination in Canada","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1046\/j.1524-4733.2003.65241.x_bib310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.1994.03510290057037","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"Lieu","year":"1994","journal-title":"JAMA"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510601696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510601696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T19:57:21Z","timestamp":1550951841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510601696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S1098301510601696"],"URL":"https:\/\/doi.org\/10.1046\/j.1524-4733.2003.65241.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}